We are delighted to announce that ME Research UK has awarded a new research grant to Prof. David Patrick at the University of British Columbia.
As a new randomised trial in Norway investigates the potential of rituximab as a treatment for ME/CFS, Prof. Patrick and his team plan to use samples from that trial in developing an immunosignature to identify those patients most likely to benefit from the drug. This is important because rituximab is associated with potentially serious side-effects and requires close monitoring.
